FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204992837> ?p ?o ?g. }

• W3204992837 abstract "Abstract Background Vericiguat is a soluble guanylate cyclase stimulator developed for the treatment of symptomatic chronic heart failure (HF) in adult patients with ejection fraction less than 45% who had a previous decompensation event. Guidelines on QT studies recommend evaluation of investigational drugs at supratherapeutic exposures in healthy volunteers. We anticipated that supratherapeutic doses of vericiguat would decrease blood pressure. We conducted an adjusted QT study using the therapeutic range of vericiguat in patients with coronary artery disease (CAD), who were expected to be more haemodynamically stable with fewer confounders (e.g., on the electrocardiogram) than a HF population. Purpose To assess the effect of vericiguat 10 mg once-daily on placebo-adjusted change from baseline of the Fridericia-corrected QT interval (QTcF) in patients with stable CAD. Methods This was a randomised, Phase Ib, placebo-controlled, double blind, double-dummy, multicentre study (NCT03504982). Test drug was vericiguat once-daily (up-titrated from 2.5 mg to 5 mg and then to 10 mg [treatments A, B, C] at 14-day intervals). The positive control was moxifloxacin 400 mg (single dose on Day 8 or Day 50 with placebo on other days [treatment D]; Figure). Patients were randomised to one of two sequences. We evaluated QTcF interval prolongation potential of vericiguat at increasing doses up to 10 mg, steady state. We investigated the pharmacokinetics, safety and tolerability of vericiguat. A clinically meaningful effect was defined as a QTcF change from baseline &gt;10 ms relative to placebo. Assay sensitivity for moxifloxacin was confirmed by the lower limit of the 90% confidence interval (CI) of the time-matched, baseline-adjusted mean difference to placebo exceeding 5 ms at &gt;1 time point. Results A total of 74 patients (66 males and 8 females) with CAD, mean (standard deviation) age 63.4 (8.0) years, were included. Mean difference between vericiguat and placebo in QTcF change from baseline (≤7 h post-dose) was &lt;6 ms; no upper limit of the 90% CIs crossed the threshold of 10 ms. Lower limits of the two-sided 90% CI of the differences between moxifloxacin and placebo in QTcF change from baseline were &gt;5 ms at 3 of 4 time points (Table). Peak plasma concentration (Cmax) of vericiguat following administration of vericiguat 10 mg was 322 μg/l and median time of maximum concentration (Tmax) was 4.5 h post-dose, in line with concentrations observed following administration of vericiguat 10 mg to patients with HF [1]. For moxifloxacin 400 mg, Cmax was 1960 μg/l and median Tmax was 3 h post-dose, in line with previously reported values [2]. Vericiguat up to 10 mg was generally safe and well tolerated. Conclusion This study supports the assessment that administration of vericiguat 10 mg is not associated with clinically meaningful QTc prolongation. These data contribute to the overall safety profile of vericiguat for the treatment of patients with HF. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Funding was provided by Bayer AG, Berlin, Germany, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA QTc study design" @default.
• W3204992837 created "2021-10-25" @default.
• W3204992837 creator A5014177046 @default.
• W3204992837 creator A5025972354 @default.
• W3204992837 creator A5026830338 @default.
• W3204992837 creator A5030880541 @default.
• W3204992837 creator A5033245007 @default.
• W3204992837 creator A5037371315 @default.
• W3204992837 creator A5041217307 @default.
• W3204992837 creator A5042865492 @default.
• W3204992837 creator A5056136043 @default.
• W3204992837 creator A5057962160 @default.
• W3204992837 creator A5068846586 @default.
• W3204992837 creator A5075947367 @default.
• W3204992837 creator A5082519884 @default.
• W3204992837 creator A5090126429 @default.
• W3204992837 date "2021-10-01" @default.
• W3204992837 modified "2023-10-18" @default.
• W3204992837 title "Vericiguat: a QTc interval study in patients with coronary artery disease" @default.
• W3204992837 doi "https://doi.org/10.1093/eurheartj/ehab724.0922" @default.
• W3204992837 hasPublicationYear "2021" @default.
• W3204992837 type Work @default.
• W3204992837 sameAs 3204992837 @default.
• W3204992837 citedByCount "1" @default.
• W3204992837 countsByYear W32049928372023 @default.
• W3204992837 crossrefType "journal-article" @default.
• W3204992837 hasAuthorship W3204992837A5014177046 @default.
• W3204992837 hasAuthorship W3204992837A5025972354 @default.
• W3204992837 hasAuthorship W3204992837A5026830338 @default.
• W3204992837 hasAuthorship W3204992837A5030880541 @default.
• W3204992837 hasAuthorship W3204992837A5033245007 @default.
• W3204992837 hasAuthorship W3204992837A5037371315 @default.
• W3204992837 hasAuthorship W3204992837A5041217307 @default.
• W3204992837 hasAuthorship W3204992837A5042865492 @default.
• W3204992837 hasAuthorship W3204992837A5056136043 @default.
• W3204992837 hasAuthorship W3204992837A5057962160 @default.
• W3204992837 hasAuthorship W3204992837A5068846586 @default.
• W3204992837 hasAuthorship W3204992837A5075947367 @default.
• W3204992837 hasAuthorship W3204992837A5082519884 @default.
• W3204992837 hasAuthorship W3204992837A5090126429 @default.
• W3204992837 hasBestOaLocation W32049928371 @default.
• W3204992837 hasConcept C118441451 @default.
• W3204992837 hasConcept C126322002 @default.
• W3204992837 hasConcept C142724271 @default.
• W3204992837 hasConcept C164705383 @default.
• W3204992837 hasConcept C197934379 @default.
• W3204992837 hasConcept C204787440 @default.
• W3204992837 hasConcept C27081682 @default.
• W3204992837 hasConcept C2778198053 @default.
• W3204992837 hasConcept C2778213512 @default.
• W3204992837 hasConcept C2778375690 @default.
• W3204992837 hasConcept C2778836808 @default.
• W3204992837 hasConcept C2908647359 @default.
• W3204992837 hasConcept C42219234 @default.
• W3204992837 hasConcept C501593827 @default.
• W3204992837 hasConcept C71924100 @default.
• W3204992837 hasConcept C78085059 @default.
• W3204992837 hasConcept C86803240 @default.
• W3204992837 hasConcept C89423630 @default.
• W3204992837 hasConcept C99454951 @default.
• W3204992837 hasConceptScore W3204992837C118441451 @default.
• W3204992837 hasConceptScore W3204992837C126322002 @default.
• W3204992837 hasConceptScore W3204992837C142724271 @default.
• W3204992837 hasConceptScore W3204992837C164705383 @default.
• W3204992837 hasConceptScore W3204992837C197934379 @default.
• W3204992837 hasConceptScore W3204992837C204787440 @default.
• W3204992837 hasConceptScore W3204992837C27081682 @default.
• W3204992837 hasConceptScore W3204992837C2778198053 @default.
• W3204992837 hasConceptScore W3204992837C2778213512 @default.
• W3204992837 hasConceptScore W3204992837C2778375690 @default.
• W3204992837 hasConceptScore W3204992837C2778836808 @default.
• W3204992837 hasConceptScore W3204992837C2908647359 @default.
• W3204992837 hasConceptScore W3204992837C42219234 @default.
• W3204992837 hasConceptScore W3204992837C501593827 @default.
• W3204992837 hasConceptScore W3204992837C71924100 @default.
• W3204992837 hasConceptScore W3204992837C78085059 @default.
• W3204992837 hasConceptScore W3204992837C86803240 @default.
• W3204992837 hasConceptScore W3204992837C89423630 @default.
• W3204992837 hasConceptScore W3204992837C99454951 @default.
• W3204992837 hasIssue "Supplement_1" @default.
• W3204992837 hasLocation W32049928371 @default.
• W3204992837 hasOpenAccess W3204992837 @default.
• W3204992837 hasPrimaryLocation W32049928371 @default.
• W3204992837 hasRelatedWork W2035777806 @default.
• W3204992837 hasRelatedWork W2059530273 @default.
• W3204992837 hasRelatedWork W2091139515 @default.
• W3204992837 hasRelatedWork W2104371670 @default.
• W3204992837 hasRelatedWork W2355594703 @default.
• W3204992837 hasRelatedWork W2964563167 @default.
• W3204992837 hasRelatedWork W3033076790 @default.
• W3204992837 hasRelatedWork W3155674270 @default.
• W3204992837 hasRelatedWork W3187572025 @default.
• W3204992837 hasRelatedWork W4213257986 @default.
• W3204992837 hasVolume "42" @default.
• W3204992837 isParatext "false" @default.
• W3204992837 isRetracted "false" @default.
• W3204992837 magId "3204992837" @default.
• W3204992837 workType "article" @default.